初始立体定向放射外科疗程后症状性颅内进展的决定因素
这项多机构回顾性队列研究纳入2015至2020年完成初始立体定向放射外科(SRS)的脑转移患者1383例,中位随访8.72个月,无症状和有症状颅内进展(ITCP)分别见于504例(36%)和194例(14%)。有症状ITCP患者总生存(OS)更差(中位10.2 vs 17.9个月,P<.001),且与总治疗体积、黑色素瘤组织学、既往全脑放疗等因素相关。
要点
- 有症状颅内进展患者中位OS为10.2个月,无症状者为17.9个月(P<.001)。
- 多数颅内进展为远处进展,占79.5%。
- 年轻及SRS后接受化疗、免疫治疗或靶向/小分子抑制剂治疗者无有症状颅内进展生存更好。
核心结论
- 在完成SRS的脑转移患者队列中,颅内进展时的神经系统症状对总生存具有预后意义。
- 该数据为临床实践中的SRS后监测以及未来脑转移现代管理的前瞻性研究提供了信息。
研究设计与样本
- 这是一项多机构回顾性队列研究,时间范围为2015年至2020年,纳入所有完成初始SRS疗程的脑转移患者。
- 共纳入1383例患者,中位年龄63.4岁,55%为女性。
- 常见原发肿瘤为非小细胞肺癌(49%)、乳腺癌(15%)和黑色素瘤(9%)。
- 主要结局为按颅内进展时是否存在神经系统症状划分的总生存。
主要发现
- 中位随访8.72个月时,无症状和有症状颅内进展分别见于504例(36%)和194例(14%)患者。
- 颅内进展多数为远处进展,占79.5%。
- 有症状颅内进展患者的总生存更差,中位10.2 vs 17.9个月(P<.001)。
- 有症状颅内进展与总治疗体积(P=.012)、黑色素瘤组织学(P=.001)、既往全脑放疗(P=.003)、脑转移数目(P<.001)、原发肿瘤与脑转移诊断间隔1至2年(P=.012)、颅外疾病受控(P=.042)及SRS前接受化疗(P=.015)等临床因素相关。
- 年轻及SRS后接受化疗(P=.001)、免疫治疗(P<.001)和靶向或小分子抑制剂治疗(P<.026)的患者无有症状颅内进展生存更好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical and imaging surveillance of patients with brain metastases is important after stereotactic radiosurgery (SRS) because many will experience intracranial progression (ITCP) requiring multidisciplinary management. The prognostic significance of neurologic symptoms at the time of ITCP is poorly understood. METHODS AND MATERIALS: This was a multi-institutional, retrospective cohort study from 2015 to 2020, including all patients with brain metastases completing an initial course of SRS. The primary outcome was overall survival (OS) by presence of neurologic symptoms at ITCP. OS, freedom from ITCP (FF-ITCP), and freedom from symptomatic ITCP (FF-SITCP) were assessed via Kaplan-Meier method. Cox proportional hazard models tested parameters impacting FF-ITCP and FF-SITCP. RESULTS: Among 1383 patients, median age was 63.4 years, 55% were female, and common primaries were non-small cell lung (49%), breast (15%), and melanoma (9%). At a median follow-up of 8.72 months, asymptomatic and symptomatic ITCP were observed in 504 (36%) and 194 (14%) patients, respectively. The majority of ITCP were distant ITCP (79.5%). OS was worse with SITCP (median, 10.2 vs 17.9 months, P < .001). SITCP was associated with clinical factors including total treatment volume (P = .012), melanoma histology (P = .001), prior whole brain radiation therapy (P = .003), number of brain metastases (P < .001), interval of 1 to 2 years from primary and brain metastasis diagnosis (P = .012), controlled extracranial disease (P = .042), and receipt of pre-SRS chemotherapy (P = .015). Patients who were younger and received post-SRS chemotherapy (P = .001), immunotherapy (P < .001), and targeted or small-molecule inhibitor therapy (P < .026) had better FF-SITCP. CONCLUSIONS: In this cohort study of patients with brain metastases completing SRS, neurologic symptoms at ITCP is prognostic for OS. This data informs post-SRS surveillance in clinical practice as well as future prospective studies needed in the modern management of brain metastases.
引用
- Leng JX, Carpenter DJ, Huang C, et al. Determinants of Symptomatic Intracranial Progression After an Initial Stereotactic Radiosurgery Course. Adv Radiat Oncol. 2024. PMID: 38690297. doi:10.1016/j.adro.2024.101475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。